robotic device

Abstract

A robotic device is provided that allows for precise and automated administration of diosmin into animal models to investigate its cardioprotective effects in a rat model. [Solution] The robotic device of this invention integrates a robotic arm 102, a syringe pump 104, a central processing unit 106 (CPU), and sensors, enabling precise control of injection parameters such as dosage, speed, and injection site. The device supports intravenous, intraperitoneal, and subcutaneous injections and provides real-time feedback on the injection mechanism's position. It also features a stabilization mechanism to minimize movement during injection and integrates physiological monitoring tools for adjusting drug administration based on the animal's real-time response. Remote control is possible, increasing convenience and reducing the possibility of human error.

Description

[Technical Field]

[0001] The present invention relates generally to the field of biomedical research, and more particularly to the automation of drug delivery systems in preclinical animal research. More specifically, the present invention relates to a robotic device designed to deliver diosmin in a controlled and precise manner to animal models such as rats and investigate its cardioprotective effects. The present invention combines robotics, drug delivery mechanisms, and real-time physiological monitoring to improve the accuracy, reproducibility, and efficiency of preclinical cardiovascular research. [Background technology]

[0002] Cardiovascular disease (CVD) remains one of the leading causes of death worldwide. These diseases encompass a variety of conditions, including coronary artery disease, heart failure, and venous insufficiency, and are often driven by poor vascular health, oxidative stress, and inflammation. Among compounds under investigation for their potential therapeutic effects on cardiovascular health, diosmin, a flavonoid primarily found in citrus fruits, has attracted attention due to its promising pharmacological properties. Diosmin has been shown to possess antioxidant, anti-inflammatory, and vasoprotective properties, all of which may contribute to maintaining vascular health and protecting against cardiovascular disease.

[0003] Diosmin has traditionally been used to treat venous insufficiency and related conditions, such as chronic venous disease and hemorrhoids, by improving blood flow and reducing symptoms such as leg swelling and pain. It has also been studied for its potential to slow the progression of atherosclerosis, a condition in which fatty deposits build up inside arteries, and to enhance endothelial function (the function of the inner lining of blood vessels). However, despite these promising therapeutic effects, the exact mechanism by which diosmin exerts its beneficial effects on the cardiovascular system remains unclear and requires further investigation.

[0004] Research into the cardioprotective effects of diosmin, especially in preclinical animal models, is crucial to understanding how this compound can be effectively utilized in the treatment and prevention of cardiovascular disease. However, traditional drug administration methods and experimental protocols in animal studies have limitations.

[0005] In traditional nonclinical research, drugs such as diosmin are often administered to animal models using manual methods, such as oral administration, intraperitoneal (IP) injection, or intravenous (IV) injection. While these methods have been used successfully in many research settings, they have inherent drawbacks that impact the reliability and reproducibility of data. For example, manual injections are prone to human error, such as variability in dose, inaccurate injection site, and variability in injection technique. Furthermore, these manual methods often cause stress to animals, potentially affecting the physiological responses being measured and resulting in variability in experimental results. Additionally, administering multiple drugs and doses in a controlled manner requires continuous monitoring, which is labor-intensive and time-consuming.

[0006] Furthermore, the effects of diosmin on cardiovascular function are complex, and simultaneous monitoring of multiple physiological parameters, such as heart rate, blood pressure, oxygen saturation, and body temperature, is necessary to fully understand its effects on the cardiovascular system. Traditional physiological monitoring methods in animal experiments often rely on separate, manually operated devices, which are cumbersome and difficult to synchronize with drug administration. The lack of integration between drug administration and physiological monitoring limits the ability to conduct high-throughput studies and increases the likelihood of human error.

[0007] These challenges drive the need for advanced systems that can automate drug administration while ensuring accurate and consistent dosing. Such systems should also enable dynamic dose adjustments and provide real-time monitoring of animal physiological responses to ensure animal welfare during studies. An ideal solution would not only improve the accuracy and reproducibility of study results, but also streamline the research process, reduce human intervention, and provide more comprehensive data.

[0008] In recent years, the fields of robotics and machine-based systems have made great strides in automating complex processes, and these advances are beginning to be applied to biomedical research. Robotic systems equipped with sophisticated drug delivery mechanisms can overcome the limitations of manual injection methods by delivering consistent, accurate, and reproducible drug administration. Furthermore, integrating physiological monitoring capabilities can track animal health parameters in real time, providing a comprehensive understanding of drug effects.

[0009] Despite advances in robotic systems, gaps remain in the development of fully integrated robotic platforms, particularly for drug delivery in preclinical cardiovascular research. Existing systems often lack the ability to simultaneously handle multiple animals, the fine-tuned control necessary for precise drug administration, or seamless integration with various physiological monitoring tools. Therefore, a comprehensive automated system is needed that not only administers diosmin but also monitors and analyzes animals' cardiovascular responses in real time, while minimizing animal stress and maximizing experimental efficiency.

[0010] This invention addresses these challenges by providing a robotic device for the controlled administration of diosmin in rat models. The system enables precise drug administration, integrates real-time monitoring of key physiological parameters, and ensures continuous data collection and analysis. This innovation will enhance the reliability of preclinical studies, aid in determining optimal diosmin dosages and administration protocols, and ultimately contribute to the development of more effective cardiovascular therapies. Summary of the Invention [Problem to be solved by the invention]

[0011] This invention relates to a robotic device for the controlled, precise administration of diosmin into animal models, particularly rat models, for the purpose of investigating the cardioprotective effects of compounds. The device integrates a robotic arm, syringe pump, central processing unit (CPU), and a series of sensors to automate drug administration, ensure accurate dosing, and monitor physiological parameters in real time. By incorporating automation of the drug administration process and precise control of injection technique and dosage, the system reduces human error, increases experimental reproducibility, and minimizes stress on animal subjects. The device is highly flexible, allowing for various administration routes and precise adjustment of injection parameters. Furthermore, it allows for remote control, real-time data feedback, and dynamic adjustments based on the animal's physiological response, thereby improving the overall efficiency and accuracy of preclinical trials.

[0012] One object of the present invention is to provide a robotic device that automates the precise administration of diosmin into animal models, eliminating the need for manual injection and minimizing human error in the administration process.

[0013] Another object of the present invention is to incorporate a syringe pump integrated with a central processing unit (CPU) that manages all parameters of drug administration, allowing automatic and precise control of drug administration, including the rate of administration and the amount of diosmin administered.

[0014] Yet another object is to provide a robotic device capable of performing injections via multiple routes, such as intravenous, intraperitoneal, and subcutaneous, by utilizing adjustable needle or catheter attachments controlled by a central processing unit.

[0015] Furthermore, it is intended that the robotic arm provide real-time feedback on the positioning and operation of the injection mechanism, allowing for continuous adjustments during medication administration to maintain precision and accuracy.

[0016] As a further object, the present invention seeks to integrate a stabilization mechanism into the robotic arm that minimizes movement during drug injection, ensuring accurate and effective administration of diosmin while reducing variability.

[0017] An additional objective of the present invention is to incorporate a real-time physiological monitoring system within the device, allowing the operator to dynamically adjust drug administration protocols based on real-time data regarding the animal's heart rate, blood pressure, and other vital signs.

[0018] As a further object, the present invention provides a method for remotely controlling and monitoring robotic devices, thereby eliminating the need for direct manual intervention during the experimental process, thereby facilitating operation and enabling efficient high-throughput research.

[0019] The ultimate goal is to improve the overall quality and reliability of preclinical studies by reducing animal stress during drug administration, increasing reproducibility, and providing accurate data for studies on the cardioprotective effects of diosmin. [Means for solving the problem]

[0020] To achieve the above object, the present invention provides a robotic device for controlled drug delivery to an animal model, comprising: a robotic arm configured to perform precise movements, the robotic arm including an injection mechanism capable of administering diosmin to a rat model via one or more predetermined injection points, including intravenous, intraperitoneal, or subcutaneous routes; a syringe pump integrated into the robotic arm, operatively connected to the injection mechanism and enabling precise and controlled administration of diosmin in microliter amounts; and a central processing unit in communication with the robotic arm, the central processing unit controlling the movement of the robotic arm and the injection of diosmin via the syringe pump. The robotic arm is configured to manage the drug delivery process and adjust injection parameters based on a pre-set experimental protocol; adjustable parameters include dosage, injection speed, and injection site, wherein the robotic arm has a multi-joint structure that allows flexible positioning of the injection mechanism relative to the animal model, allowing the robotic device to administer diosmin at different angles and depths via various routes, including intravenous, intraperitoneal, and subcutaneous, and the robotic arm is equipped with sensors that provide feedback to a central processing unit regarding the position and movement of the injection mechanism, allowing the arm position to be continuously adjusted in real time to ensure accurate administration of diosmin. [Effects of the Invention]

[0021] The robotic device of the present invention incorporates a real-time physiological monitoring system within the device, allowing the operator to dynamically adjust drug administration protocols based on real-time data regarding the animal's heart rate, blood pressure, and other vital signs. [Brief explanation of the drawings]

[0022] These and other features, aspects, and advantages of the present disclosure will become better understood from the following detailed description when read in conjunction with the accompanying drawings.

[0023] FIG. 1 shows a block diagram of a robotic device for controlled drug administration to an animal model. FIG. 2 is a table showing that diosmin inhibits the activities of LDH, CPK, SGOT, and SGPT in cadmium-intoxicated rats. FIG. 3 is a table showing that diosmin improved lipid profiles in cadmium-intoxicated rats. FIG. 4 shows a table showing the ameliorative effect of diosmin on electrocardiogram parameters in cadmium-intoxicated rats.

[0024] Additionally, those skilled in the art will appreciate that elements in the figures are illustrated for simplicity and may not necessarily be drawn to scale. For example, a flowchart illustrates a method in terms of the most prominent steps involved to help improve understanding of aspects of the present disclosure. Furthermore, with respect to device structure, one or more components of the device may be represented in the drawings by conventional symbols, and the drawings may show only certain details relevant to understanding embodiments of the present disclosure, so as not to obscure the drawings with details that will be readily apparent to one skilled in the art having the benefit of the description herein. DETAILED DESCRIPTION OF THE INVENTION

[0025] For the purposes of promoting an understanding of the principles of the invention, reference will be made to the embodiments illustrated in the drawings and specific language will be used to describe the same, but no limitation on the scope of the invention is intended, and it is to be understood that changes and further modifications in the illustrated systems, and further applications of the principles of the invention shown therein, are within the ordinary scope of those skilled in the art.

[0026] Those skilled in the art will realize that the foregoing general description and the following detailed description are exemplary and explanatory of the invention, but are not intended to be limiting. The use of "in one aspect," "in another aspect," or similar phrases throughout this specification means that a particular feature, structure, or characteristic described in connection with an embodiment is included in at least one embodiment. Thus, the appearances of "in one embodiment," "in another embodiment," and similar phrases throughout this specification do not necessarily refer to the same embodiment.

[0027] The use of "comprises," "including," or other similar expressions is intended to be non-exclusive, and a process or method containing a list of steps does not include only those steps, but may include other steps not expressly listed or inherent in the process or method. Similarly, the use of "comprises" preceding one or more devices, subsystems, elements, structures, or components does not exclude the presence of other devices, subsystems, elements, structures, or components, or additional devices, subsystems, elements, structures, or components, unless further constrained.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The systems, methods, and examples described herein are for illustrative purposes only and are not intended to be limiting.

[0029] Embodiments of the present disclosure are described in detail below with reference to the accompanying drawings. Referring to FIG. 1, a block diagram of a robotic device for controlled drug delivery to an animal model is shown. The system 100 includes a robotic arm 102 configured for precise movement, the robotic arm including an injection mechanism capable of administering diosmin to a rat model via one or more predetermined injection points, including intravenous, intraperitoneal, or subcutaneous routes; a syringe pump 104 or other suitable drug delivery mechanism integrated into the robotic arm. The syringe pump is operatively connected to the injection mechanism to enable precise and controlled administration of diosmin in microliter amounts; and a central processing unit 106 in communication with the robotic arm. The central processing unit is configured to control the movement of the robotic arm, manage the drug delivery process via the syringe pump, and adjust injection parameters based on a pre-set experimental protocol, including adjustable parameters such as dosage, injection rate, and injection site. The parameters are programmable into the central processing unit to control the operation of the robotic arm and the syringe pump.

[0030] In one embodiment, the robotic arm 102 has a multi-jointed structure that allows for flexible positioning of the injection mechanism relative to the animal model, allowing the device to administer diosmin via various routes, such as intravenous, intraperitoneal, or subcutaneous, at various angles and depths.

[0031] In one embodiment, the syringe pump 104 is capable of delivering precise microliter doses of diosmin and is connected to a central processing unit, allowing real-time adjustments of dosage and rate based on specified experimental protocols.

[0032] In one embodiment, the system further comprises a needle 108 or catheter 110 attachment for intravenous, intraperitoneal, or subcutaneous injection, which is detachable and adjustable in length to accommodate various injection techniques, controlled by a central processing unit depending on the experimental setup.

[0033] In one embodiment, the central processing unit 106 is configured to interface with a user interface, allowing the operator to input experimental parameters, monitor drug delivery progress, and modify protocols as needed, while ensuring seamless communication between the operator and the robotic arm for real-time control.

[0034] In one embodiment, the robotic arm 102 is equipped with sensors that provide feedback to a central processing unit regarding the position and movement of the injection mechanism, allowing the arm's position to be continuously adjusted in real time to ensure accurate administration of diosmin.

[0035] In one embodiment, the central processing unit 106 is further configured to receive input from a real-time monitoring system and adjust the delivery of diosmin based on physiological feedback or experimental needs to ensure precise and dynamic control of drug administration.

[0036] In one embodiment, the injection mechanism 112 comprises a flexible, retractable catheter that can be repositioned based on real-time adjustments to the injection site or route, with its flexibility and retraction controlled by a central processing unit based on pre-set experimental parameters.

[0037] In one embodiment, the robotic arm 102 further includes a stabilization mechanism that ensures the injection mechanism remains stable during injection, minimizing animal movement and reducing variability in drug delivery.

[0038] In one embodiment, the robotic arm 102, syringe pump 104, and injection mechanism 112 are interconnected via a wireless communication system for remote control and monitoring, allowing an operator to remotely control the device and receive real-time updates on the drug administration status.

[0039] The present invention provides a robotic device designed for the controlled, precise administration of diosmin to animal models, particularly rat models, to investigate the compound's cardioprotective effects. The device automates the drug administration process, ensuring dosage consistency, minimizing human error, and enabling accurate real-time monitoring of physiological parameters. The robotic device consists of multiple interconnected components, including a robotic arm, a syringe pump, a central processing unit (CPU), and a series of sensors, all of which work together to perform automated drug administration and monitoring.

[0040] At the heart of the system is a robotic arm capable of performing precise and controlled movements. The arm is designed to hold and manipulate an injection mechanism that administers diosmin to animals through one of several pre-defined administration routes. These routes include intravenous, intraperitoneal, and subcutaneous administration, depending on experimental requirements. The robotic arm's design allows it to accommodate a variety of animal sizes while reaching the appropriate administration site with high precision, ensuring the drug is delivered precisely to the intended site.

[0041] The robotic arm is integrated with a syringe pump or other suitable drug delivery mechanism that regulates the flow rate of diosmin during injection. The syringe pump ensures microliter-level delivery of diosmin, providing a high degree of dosage accuracy. The pump is connected to a central processing unit (CPU), which acts as the control hub for the entire system. The CPU manages the operation of the robotic arm and syringe pump, guiding the arm to the correct injection site and regulating the dose, injection rate, and injection volume. It is also responsible for processing inputs from the operator and adjusting settings in real time based on experimental requirements.

[0042] The central processing unit is equipped with software that allows the operator to program various adjustable parameters, such as drug dosage, injection rate, and specific injection site. These parameters are entered into the system through a user interface, providing an easy-to-use platform for researchers to control the device. This interface allows researchers to input experimental protocols, monitor the progress of drug delivery, and make adjustments as needed. The CPU processes the input data and executes commands accordingly, ensuring the robotic arm administers diosmin in a manner consistent with the specified protocol.

[0043] The robotic arm is further equipped with sensors that provide feedback on the position and movement of the injection mechanism. These sensors ensure that the robotic arm performs precise movements and that the injection mechanism is correctly positioned relative to the animal model. Feedback from the sensors is continuously transmitted to a CPU, which adjusts the arm's position in real time to maintain precision throughout the injection process. These adjustments ensure that the medication is administered in the precise location, minimizing human error and reducing variability in experimental results.

[0044] Additionally, the system comes with a needle or catheter attachment for the injection mechanism. This attachment is adjustable in length and can be selected based on the desired route of administration, such as intravenous, intraperitoneal, or subcutaneous. It allows for flexible needle positioning, and its length is controlled by a CPU, making it adaptable to various animal models and experimental protocols. The needle or catheter attachment can be easily replaced or adjusted to accommodate different types of injections and animal sizes.

[0045] Although this robotic device is designed for autonomous operation, it can also be remotely controlled via a wireless communication system. This allows the operator to remotely manage the device and monitor the experimental status in real time. The wireless communication system ensures seamless operation without manual intervention, even during drug administration, making it particularly useful for high-throughput research and experiments requiring long-term continuous observation.

[0046] To ensure the precision of the injection process, the robotic arm also incorporates a stabilization mechanism. This mechanism keeps the administration mechanism stable during injection, preventing any movement or misalignment that could affect the accuracy of drug administration. The stabilization mechanism minimizes unintended changes in the animal's movement or position, ensuring the injection is carried out as planned.

[0047] The system is further integrated with a monitoring system capable of tracking various physiological parameters, such as heart rate, blood pressure, oxygen saturation, and body temperature, in animal models. These physiological monitoring systems provide real-time data that can be used to adjust drug administration processes and protocols based on the animal's drug response. This integration ensures that the device dynamically adapts to the condition of the animals under study, providing a more comprehensive understanding of the cardioprotective effects of diosmin.

[0048] The robotic device operates on a closed-loop feedback system, with sensors, a CPU, a syringe pump, and a robotic arm working together to ensure that diosmin administration is carried out accurately and efficiently. Real-time monitoring data allows the operator to observe the drug's immediate physiological effects on the animal model and adjust the dosage and injection technique as needed. This automated, integrated approach significantly reduces human error and variability, ensuring consistent, reproducible, and reliable experimental results.

[0049] This device represents a significant advancement over traditional manual drug administration methods by providing an automated, precise, and efficient system for drug administration in preclinical cardiovascular research. The integration of robotic technology with real-time physiological monitoring not only improves the accuracy of drug administration but also enhances the overall quality and reliability of experimental data. Furthermore, the system minimizes animal handling, reducing stress and ensuring that studies are conducted under high animal welfare standards. This robotic device is applicable in a wide range of settings, from small-scale research to large-scale drug development, providing a scalable solution for preclinical studies investigating the cardiovascular effects of diosmin and other compounds.

[0050] Experiment details Male Wistar rats (n = 6) were assigned equally to four groups after 1 week of acclimation. The Cd solution was freshly prepared in normal saline immediately before administration. Similarly, the diosmin suspension was freshly prepared in 0.3% w / v carboxymethylcellulose (CMC) before administration.

[0051] In each group, animals received the following treatments: Group I received 0.3% CMC orally (1 ml / kg), group II received Cd (5 mg / kg; po) alone, group III received diosmin (100 mg / kg; po) and Cd (5 mg / kg; po), and group IV received diosmin (200 mg / kg; po) and Cd (5 mg / kg; po).

[0052] For a total of 28 days, the rats received the corresponding treatment described in each group. At the end of the study, the animals were subjected to electrocardiogram analysis (QT prolongation, RR interval, heart rate) to examine the cardiac physiological abnormalities (if any) of the rats using a Biopac MP36 device [4,7].

[0053] Biochemical markers On the 28th day, the rats were fasted for 24 hours, and then blood was collected by cardiac puncture under ether anesthesia, and biochemical evaluations such as lipid profile, LDH, SGOT, and SGPT were performed.

[0054] Additionally, the amounts of NO, TNF-α, IL-1β, and IL-10 in cardiac tissue homogenates were measured. Heart homogenates (10% w / v) were prepared using 50 mM Tris phosphate buffer, pH 7.4. The homogenates were centrifuged at 3000 rpm for 10 minutes at 4°C. The amounts of NO, pro-inflammatory cytokines (TNF-α and IL-1β), and anti-inflammatory cytokine (IL-10) in the supernatant were measured using commercially available ELISA kits. Measurement of the above biochemical markers was performed according to the respective manufacturer's instructions [4].

[0055] Data analysis One-way analysis of variance (ANOVA) and Dunnett's test were used to establish the statistical significance of the results. Results are presented as mean ± standard deviation (Mean ± SD).

[0056] result In acute oral toxicity studies, no abnormal behavioral changes, toxic symptoms, or death were observed in rats at doses up to 2000 mg / kg. Therefore, doses of 100 and 200 mg / kg were examined in this study. Serum LDH, SGOT, and SGPT levels: Statistically significant increases in both LDH and CPK enzyme activities were observed in the Cd-treated group (Table 1). Furthermore, significant increases in both SGOT and SGPT activity were observed after Cd administration. Meanwhile, all of the enzyme activities were significantly inhibited by diosmin (100 and 200 mg / kg). Furthermore, the inhibitory effect was more pronounced with higher doses of diosmin.

[0057] Figure 2 shows that diosmin inhibited the activity of LDH, CPK, SGOT, and SGPT in Cd-intoxicated rats. The data in the table are shown as mean ± standard deviation. (###) P<0.001 for the comparison between the Cd-treated group and the normal control group, (**) P<0.01 for the comparison between the diosmin-treated group and the Cd-treated group, and (*) P<0.05 for the comparison between the diosmin-treated group and the Cd-treated group. Cholesterol, triglyceride, and LDL levels all significantly increased after Cd administration. Meanwhile, HDL levels significantly decreased after Cd administration. When diosmin was coadministered with diosmin (100 and 200 mg / kg), cholesterol, triglyceride, and LDL levels all significantly decreased. Furthermore, diosmin significantly increased HDL levels. The effect was more pronounced at a higher dose (200 mg / kg). Figure 3 shows that diosmin improved the lipid profile in Cd-intoxicated rats. The data in the table are shown as mean ± standard deviation. (###) P<0.001 for the comparison between the Cd-treated control group and the normal control group, (***) P<0.001 for the comparison between the diosmin-treated group and the Cd-treated control group, (**) P<0.01, and (*) P<0.05.

[0058] Figure 4 shows the ameliorating effects of diosmin on ECG parameters in Cd-intoxicated rats. The data in the table in Figure 4 are shown as mean ± standard deviation. ## P value <0.01 when comparing the Cd-control group with the normal control group; * P value <0.05 when comparing the diosmin-treated group with the Cd-control group. The results of this study suggest that the QT and RR intervals were prolonged in Cd-loaded animals, which may promote ventricular arrhythmias and, consequently, be associated with an increase in overall mortality from cardiovascular causes. The table in Figure 4 lists the effects of diosmin on several ECG parameters. The QT and RR intervals were significantly increased in Cd-control animals, which are symptoms of cardiac arrhythmias. Comparing the Cd-control group with the standard control group, the heart rate in the Cd-control group was significantly decreased. Administration of SE extract (100 and 200 mg / kg) significantly shortened the QT and RR intervals and increased the heart rate in Cd-treated animals.

[0059] The drawings and the foregoing description illustrate examples of embodiments. Those skilled in the art will understand that one or more of the described elements may be combined into a single functional element. Alternatively, certain elements may be divided into multiple functional elements. Elements from one embodiment may be added to another embodiment. For example, the order of processes described herein may be changed and is not limited to the methods described herein. Furthermore, the operations in the flow diagrams need not be implemented in the order shown, and not all operations necessarily need to be performed. Furthermore, operations that are independent of other operations may be performed in parallel with other operations. The scope of the embodiments is in no way limited by these specific examples. Numerous variations are possible, including differences in structure, dimensions, use of materials, and the like, whether or not explicitly described in the specification. The scope of the embodiments is at least as broad as that given by the following claims.

[0060] Advantages Advantages, other advantages, and solutions to problems have been described above with respect to particular embodiments. However, the advantages, benefits, solutions to problems, and elements that may cause any advantage, benefit, or solution to occur or be realized should not be construed as required, necessary, or essential features or elements of any claim or all claims.

Claims

1. 1. A robotic device for controlled drug delivery to an animal model, comprising: a robotic arm configured to perform precision movements, said robotic arm including an injection mechanism capable of administering diosmin to the rat model via one or more predetermined injection points, including intravenous, intraperitoneal, or subcutaneous routes; a syringe pump integrated into said robotic arm, operatively connected to said injection mechanism, allowing for precise and controlled administration of Diosmin in microliter quantities; a central processing unit in communication with the robotic arm, the central processing unit configured to control the movement of the robotic arm, manage a drug delivery process via the syringe pump, and adjust injection parameters based on a pre-set experimental protocol; a set of adjustable parameters including dosage, injection speed, and injection site, wherein the robotic arm has a multi-joint structure that allows for flexible positioning of the injection mechanism relative to the animal model, so that the robotic device can administer diosmin at different angles and depths through various routes including intravenous, intraperitoneal, and subcutaneous; The robotic arm is equipped with sensors that provide feedback on the position and movement of the injection mechanism to a central processing unit, allowing it to continuously adjust the arm's position in real time to ensure accurate administration of diosmin.

2. 2. The robot device according to claim 1, The injection mechanism comprises a flexible, retractable catheter that can be repositioned based on real-time adjustments to the injection site or route, the flexibility and retraction of which is controlled by the central processing unit based on pre-set experimental parameters.

Images